You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
Clinical course of MOG antibody-associated recurrent demyelinating diseases

https://doi.org/10.1136/jnnp-2017-317249

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors The author wrote the commentary solely.

    • Competing interests The Neurological Research Laboratory (Medical University of Innsbruck and Tirol Kliniken, Innsbruck, Austria) receives payments for antibody assays (AQP4 and antineuronal antibodies) and for MOG and AQP4 antibody validation experiments organised by Euroimmun (Germany).

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles

    • Neuro-inflammation
      Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination
      Sudarshini Ramanathan Shekeeb Mohammad Esther Tantsis Tina Kim Nguyen Vera Merheb Victor S C Fung Owen Bruce White Simon Broadley Jeannette Lechner-Scott Steve Vucic Andrew P D Henderson Michael Harry Barnett Stephen W Reddel Fabienne Brilot Russell C Dale on behalf of the Australasian and New Zealand MOG Study Group Pi Andrews Jl Barton Jnc Burrow H Butzkueven Ag Cairns S Calvert P Caruana S Chelakkadan D Clark Cl Fraser Jl Freeman D Gill Pj Grattan-smith S Gupta Ta Hardy K Kothur Sr Ling Ja Lopez S Malone Mp Marriott M Nosadini Gl O’grady Cf Orr R Ouvrier J Parratt E Patrick D Pilli Ds Riminton K Riney V Rodriguez-casero Mm Ryan Ie Scheffer Uh Shah N Shuey Cg Spooner Gm Subramanian F Tea T Thomas J Thompson C Troedson Tl Ware Ri Webster C Yiannikas Em Yiu A Zou
      Journal of Neurology, Neurosurgery & Psychiatry 2017; 89 127-137 Published Online First: 15 Nov 2017. doi: 10.1136/jnnp-2017-316880